Cell and Gene Outsourcing

  1. Lentiviral Packaging & Producer Cell Lines For LVV Manufacturing 6/5/2026

    Stable lentiviral vector line platforms enable scalable, cost-efficient manufacturing by reducing plasmids, simplifying processes, improving consistency, and supporting volume production.

  2. Advancing Viral Safety With Next-Generation Sequencing 6/4/2026

    Discover how advanced sequencing and bioinformatics technologies are helping shape the future of viral safety assessment in biopharmaceutical manufacturing.

  3. Unmatched Beginnings For Late-Phase Success 6/2/2026

    Early research choices shape outcomes. Focusing on reproducibility, scalability, regulatory fit, and supply stability early cuts risk, prevents delays, and supports smoother development progress.

  4. How Real-Time Visibility Is Changing Outsourced Gene Therapy Programs 6/2/2026

    Outsourced gene therapy programs suffer from fragmented, lagging visibility across CDMO networks, and a real-time integrated operating model unifies execution, governance, and risk data to enable continuous insight, faster decisions, and more reliable delivery.

  5. End-To-End Process Scalability Of HEK 293 Media For High Titer AAV Production 6/2/2026

    Explore how controlled bioreactor environments enable optimization of critical process parameters and support robust, scalable AAV production from development through manufacturing.

  6. From Complexity To Confidence: Supporting Tech Transfer With A Prefillable Syringe System 6/2/2026

    Discover how aligning packaging strategy with technology transfer requirements can accelerate timelines, control costs, and support successful injectable drug product manufacturing.

  7. Challenges And Opportunities With Novel AAV Capsids 6/2/2026

    Explore challenges and solutions in developing novel AAV capsids, focusing on manufacturing complexity, analytical testing, and regulatory considerations for advancing gene therapy effectiveness.

  8. Madison: Clinical, Commercial Drug Substance Development 6/2/2026

    Catalent Madison offers gene-to-GMP drug substance in 8 months via GPEx Lightning CHO cell lines, hitting 15+ g/L, backed by 24 approved products and 5 GMP trains up to 4,000 L.

  9. Bridging Studies For Producer Cell Line Adoption: Regulatory And Development Perspectives 6/1/2026

    Explore how analytical comparability, risk assessment, and bridging strategies can support a smooth and compliant platform transition.

  10. Accelerate Your Next In Vivo CAR-T Program 6/1/2026

    Explore how Lonza supports complex in vivo modalities with scalable manufacturing solutions, advanced analytics, and end to end CMC expertise across viral vector and RNA LNP platforms, from early development through clinical readiness.